Veranstaltungsempfehlung: 12. Klinische Pharmazie-Update-Seminar, 10. und 11. September 2021, Wiesbaden
A pooled analysis on therapy response and prognosis of patients with low HR-positive, HER2-negative early breast cancer has been published in European Journal of Cancer
We are happy to inform you that results of several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Annual Meeting 2021, which will take place from 4 to 8 June.
The International Immuno-Oncology Biomarker Working Group has launched a global survey on the potential use of Tumor Infiltrating Lymphocytes (TILs) for future trial designs and use in daily practice.
GBG Forschungs GmbHMartin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440
+49 6102 7480-0 | nfGBGd